Skip to main content
. Author manuscript; available in PMC: 2015 Aug 4.
Published in final edited form as: J Clin Cell Immunol. 2014 Nov 19;5(6):1000273. doi: 10.4172/2155-9899.1000273

Figure 5.

Figure 5

The serum cytokine levels of IL-6 of mice treated with PBS, CII-2, and CII-BPI-2 on days 31 and 44. A, Mice treated with three injections of CII-BPI-2 have significantly lower levels of IL-6 in the serum than those injected with PBS (*, p<0.0001) and three injections of CII-2 (#, p<0.0001). Serum IL-6 levels are significantly higher on day 31 in the mice treated with CII-2 than in PBS-treated mice (‡, p<0.0001). Serum levels of the cytokine IL-6 are significantly lower on day 44 after three injections of CII-2 (*, p<0.0001) and CII-BPI-2 (*, p<0.0001) compared to PBS. A significant difference between IL-6 levels of CII-2 and CII-BPI-2 on day 44 was not observed. B, Comparison of serum IL-6 levels of mice treated with four injections of PBS, CII-2, and CII-BPI-2 on days 31 and 44. Serum IL-6 levels are significantly higher in the CII-2 group compared to the PBS group (‡, p<0.0001) and CIIBPI-2 (*, p<0.0001). Significant differences between IL-6 levels of CII-BPI-2 and PBS were not observed. On day 44, serum IL-6 levels were significantly higher in the PBS-treated group compared to the CII-2 (*, p<0.0001) and CII-BPI-2 groups (*, p<0.0001). No significant difference in IL-6 levels was observed between CII-2 and CII-BPI-2 treated groups on day 44.